Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.
Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.
A study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one day ...
A new study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one day be an effective treatment for traumatic brain injury (TBI).
Childhood psychiatrists insist the drugs, for attention-deficit/hyperactivity disorder (ADHD) and depression, are nonaddictive and proven safe and say they are more concerned about young Americans ...
The FDA has issued a recall for a nasal wash product after it tested positive for dangerous bacteria. Ascent Consumer ...
Nasal decongestants, often used during cold and allergy seasons, can negatively impact brain health when used long-term or in ...
Feb. 5, 2025 — New research has shown that diet could influence the risk of both depression and Alzheimer's disease (AD). Evidence suggests that depressive symptoms ...